KR20260042289A - 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 - Google Patents
당뇨병, 간염 및/또는 염증성 간질환의 치료 방법Info
- Publication number
- KR20260042289A KR20260042289A KR1020267006914A KR20267006914A KR20260042289A KR 20260042289 A KR20260042289 A KR 20260042289A KR 1020267006914 A KR1020267006914 A KR 1020267006914A KR 20267006914 A KR20267006914 A KR 20267006914A KR 20260042289 A KR20260042289 A KR 20260042289A
- Authority
- KR
- South Korea
- Prior art keywords
- diabetes
- subject
- antibody
- liver
- pancreatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862618332P | 2018-01-17 | 2018-01-17 | |
| US62/618,332 | 2018-01-17 | ||
| KR1020207022117A KR102937161B1 (ko) | 2018-01-17 | 2019-01-17 | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 |
| PCT/US2019/013934 WO2019143767A1 (en) | 2018-01-17 | 2019-01-17 | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207022117A Division KR102937161B1 (ko) | 2018-01-17 | 2019-01-17 | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20260042289A true KR20260042289A (ko) | 2026-03-30 |
Family
ID=65324621
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267006914A Pending KR20260042289A (ko) | 2018-01-17 | 2019-01-17 | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 |
| KR1020207022117A Active KR102937161B1 (ko) | 2018-01-17 | 2019-01-17 | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207022117A Active KR102937161B1 (ko) | 2018-01-17 | 2019-01-17 | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11866488B2 (https=) |
| EP (2) | EP3740282B1 (https=) |
| JP (2) | JP7486423B2 (https=) |
| KR (2) | KR20260042289A (https=) |
| CN (2) | CN111801140B (https=) |
| AU (2) | AU2019209491B2 (https=) |
| BR (1) | BR112020014346A2 (https=) |
| CA (1) | CA3088661A1 (https=) |
| EA (1) | EA202091533A1 (https=) |
| ES (1) | ES3033317T3 (https=) |
| HR (1) | HRP20250727T1 (https=) |
| HU (1) | HUE072418T2 (https=) |
| IL (2) | IL316486A (https=) |
| MX (1) | MX2020007384A (https=) |
| PH (1) | PH12020551076A1 (https=) |
| PL (1) | PL3740282T3 (https=) |
| RS (1) | RS66918B1 (https=) |
| SG (1) | SG11202006421RA (https=) |
| SM (1) | SMT202500233T1 (https=) |
| WO (1) | WO2019143767A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3934677A4 (en) | 2019-03-13 | 2022-11-16 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS TO PROMOTE ISLAND VIABILITY AND INCREASE INSULINE SECRETION |
| AU2020315367A1 (en) | 2019-07-15 | 2022-02-03 | University Of Connecticut | Metallothionein antibodies and their use |
| CN110551726B (zh) * | 2019-09-06 | 2021-04-09 | 上海市肺科医院 | 一种结核杆菌阿拉伯半乳聚糖适配子及其应用 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| KR102191405B1 (ko) * | 2020-09-15 | 2020-12-16 | 주식회사 에이스바이오메드 | 간 질환 예방 또는 치료용 조성물 |
| CN115317502B (zh) * | 2021-12-21 | 2023-07-07 | 青岛市市立医院 | 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用 |
| WO2025226837A1 (en) * | 2024-04-24 | 2025-10-30 | University Of Connecticut | Anti-bacterial metallothionein antibodies and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20030007973A1 (en) * | 2001-06-22 | 2003-01-09 | Lynes Michael A. | Methods and compositions for manipulation of the immune response using anti-metallothionein antibody |
| US8658174B2 (en) | 2005-07-27 | 2014-02-25 | Qinghua Wang | GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes |
| CN102725312B (zh) * | 2009-10-20 | 2014-10-01 | 佐治亚州立大学研究基金会公司 | 用于糖尿病治疗和β细胞成像的蛋白药物 |
| WO2012050500A1 (en) | 2010-10-14 | 2012-04-19 | Lars Pettersson | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
| US20140141009A1 (en) * | 2011-07-08 | 2014-05-22 | Univeristy Of Connecticut | Use of antagonists targeting metallothionein to treat intestinal inflammation |
| US20160215042A1 (en) * | 2013-04-19 | 2016-07-28 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
| TR201402685A1 (tr) | 2014-03-06 | 2015-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vildagliptinin farmasotik formulasyonları. |
| US10695406B2 (en) * | 2014-05-27 | 2020-06-30 | The University Of Queensland | Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent |
| KR20170033439A (ko) | 2014-08-07 | 2017-03-24 | 레굴루스 테라퓨틱스 인크 | 대사 장애에 대한 마이크로rna의 표적화 |
-
2019
- 2019-01-17 EP EP19703874.8A patent/EP3740282B1/en active Active
- 2019-01-17 CN CN201980008316.6A patent/CN111801140B/zh active Active
- 2019-01-17 EP EP25158063.5A patent/EP4596042A3/en active Pending
- 2019-01-17 KR KR1020267006914A patent/KR20260042289A/ko active Pending
- 2019-01-17 SG SG11202006421RA patent/SG11202006421RA/en unknown
- 2019-01-17 RS RS20250601A patent/RS66918B1/sr unknown
- 2019-01-17 ES ES19703874T patent/ES3033317T3/es active Active
- 2019-01-17 CA CA3088661A patent/CA3088661A1/en active Pending
- 2019-01-17 IL IL316486A patent/IL316486A/en unknown
- 2019-01-17 PL PL19703874.8T patent/PL3740282T3/pl unknown
- 2019-01-17 JP JP2020537722A patent/JP7486423B2/ja active Active
- 2019-01-17 HR HRP20250727TT patent/HRP20250727T1/hr unknown
- 2019-01-17 US US16/961,327 patent/US11866488B2/en active Active
- 2019-01-17 SM SM20250233T patent/SMT202500233T1/it unknown
- 2019-01-17 MX MX2020007384A patent/MX2020007384A/es unknown
- 2019-01-17 KR KR1020207022117A patent/KR102937161B1/ko active Active
- 2019-01-17 WO PCT/US2019/013934 patent/WO2019143767A1/en not_active Ceased
- 2019-01-17 BR BR112020014346-4A patent/BR112020014346A2/pt unknown
- 2019-01-17 CN CN202510512846.1A patent/CN120267797A/zh active Pending
- 2019-01-17 AU AU2019209491A patent/AU2019209491B2/en active Active
- 2019-01-17 IL IL276097A patent/IL276097B2/en unknown
- 2019-01-17 HU HUE19703874A patent/HUE072418T2/hu unknown
- 2019-01-17 EA EA202091533A patent/EA202091533A1/ru unknown
-
2020
- 2020-07-14 PH PH12020551076A patent/PH12020551076A1/en unknown
-
2022
- 2022-08-12 AU AU2022215285A patent/AU2022215285B2/en active Active
-
2023
- 2023-07-24 US US18/357,632 patent/US12583916B2/en active Active
- 2023-10-27 US US18/496,279 patent/US20240067710A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002422A patent/JP2024028454A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102937161B1 (ko) | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 | |
| JP6633108B2 (ja) | 脂肪組織の集積を処置するための組成物および方法 | |
| JP2009526756A (ja) | Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法 | |
| JP2021511296A5 (https=) | ||
| JP2013518863A (ja) | 代謝障害の治療 | |
| KR20250016223A (ko) | 항인슐린 수용체 항체를 위한 제형 및 이의 용도 | |
| US20190015479A1 (en) | Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis | |
| WO2017062693A1 (en) | Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies | |
| HK40129169A (en) | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| RS60316B1 (sr) | Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21 | |
| EA048509B1 (ru) | Способы лечения диабета, гепатита и/или воспалительного заболевания печени | |
| HK40040177A (en) | Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| HK40040177B (en) | Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| HK1257377B (en) | Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |